Standard of care for COVID-19 in randomized clinical trials registered in trial registries and published in preprint servers and scholarly journals: a cross-sectional study

Table 2 Groups of interventions used in standard of care (SoC) in all trials that described the SoC (N = 129), and in three subgroups: trials that included outpatients (N = 7), both hospitalized patients and outpatients (N = 7) or hospitalized patients only (N = 101))

Intervention	N (%) and [range]^b of trials that used the intervention (*N =* 129)	N (%) and [range]^bof trials that included outpatients (*N =* 7)	N (%) and [range]^b of trials that included both hospitalized and outpatients (*N =* 7)	N (%) and [range]^b of trials that included hospitalized (*N =* 101)
Antiparasitics	80 (62) [1 to 2]	4 (57) [1]	5 (71) [1 to 2]	62 (61) [1 to 2]
Antivirals	73 (57) [1 to 4]	–	2 (28) [1]	64 (63) [1 to 4]
Antibiotics	40 (31) [1 to 4]	2 (28) [1]	2 (28) [1]	34 (37) [1 to 4]
Oxygen	19 (17) [1]	–	1 (14) [1]	14 (14) [1]
Antithrombotics/anticoagulants	18 (14) [1 to 2]	–	2 (28) [1 to 2]	16 (16) [1 to 2]
Vitamins	17 (13) [1 to 4]	2 (28) [1]	3 (43) [1]	5 (5) [1 to 4]
Immunomodulatory agents	17 (13) [1 to 2]	–	1 (14) [1]	13 (13) [1 to 2]
Corticosteroids	16 (12) [1 to 2]	–	1 (14) [1]	14 (14) [1 to 2]
Analgesics/antipyretics	16 (12) [1]	4 (57) [1]	1 (14) [1]	9 (9) [1]
Other^a	28 (22) [1 to 5]	1 (14) [1]	–	16 (16) [1 to 5]

^aDescribed in detail in Supplementary file 7; examples include Antitussives, Bromhexine, Convalescent plasma, Ketamine, etc.
^aSquare brackets denote the range of the number of interventions used in the analyzed trials if more than one intervention from that group was used in a single trial; for example, among trials that used antiparasitics, some trials used 1 antiparasitic, others used 2 antiparasitics. Among trials that used antivirals, some trials used as many as 4 antivirals, etc.

ISSN: 1471-2288